NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive(R) to Exhibit Innovative Products and Procedures at IMAST 2013

SAN DIEGO, CA -- (Marketwired) -- 07/10/13 -- NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to announce their participation at the 20th International Meeting on Advanced Spine Techniques (IMAST) from Wednesday, July 10, to Saturday, July 13, 2013, in booth #303 at the Vancouver Convention Center in British Columbia.

Sponsored by the Scoliosis Research Society, IMAST gathers over 600 world renowned spine surgeons and industry leaders to present and discuss innovative research and advanced spine technologies in an international forum. The Scoliosis Research Society is a global organization dedicated to education, research, and treatment of spinal deformities.

"NuVasive is excited to return to IMAST to feature our innovative products and procedures and to interact with some of the world's leading spine surgeons," said NuVasive Chairman and CEO Alex Lukianov. "The meeting will also advance our initiative to differentiate NuVasive's solutions with clinical evidence, which will be prominent in several podium and poster presentations and clinical papers."

As an industry sponsor of IMAST, NuVasive will exhibit and demonstrate the Company's game changing products and procedures, including XLIF®, Precept, Armada®, the PCM® Cervical Disc, and MAS® PLIF.

Additionally, two clinical papers featuring NuVasive's solutions have been nominated for the prestigious Thomas Whitecloud Award, an award that recognizes the best basic science and clinical paper at IMAST.

NuVasive is scheduled to participate in the following events at IMAST:

  • NuVasive Technical Exhibit Booth #303: The NuVasive exhibit booth will feature a number of innovative, minimally disruptive products and procedures.

  • NuVasive Hands-on Workshop: NuVasive, along with surgeon proctors Behrooz Akbarnia, M.D., Virginie Lafage, M.D., and Juan Uribe, M.D., will host a hands-on workshop on Thursday, July 11, 2013, from 12:00 to 1:00 p.m. PST. The workshop, titled Anterior Column Realignment: MAS Techniques to Restore Sagittal Balance, will discuss the sagittal and pelvic parameters and the overall importance of global spinal balance.

  • Clinical Papers: Podium presentations will feature several NuVasive products, including the PCM Cervical Disc, XLIF, XLIF ACR™ (Anterior Column Realignment), and Osteocel® Plus. XLIF will also be highlighted in four poster presentations.

  • The Thomas Whitecloud Award Nominees: NuVasive is proud to announce that two clinical papers have been nominated for the 2013 Thomas Whitecloud Award. The clinical paper nominees are: "A Prospective, Randomized Clinical Investigation of the PCM Cervical Disc: Five-Year Results from US IDE Study," by Dr. Frank Phillips et al., and "Comparison of Radiographic Results after Minimally Invasive (MIS), Hybrid, and Open Surgery for Adult Spinal Deformity: A Multi-Center Study of 184 Patients," by Dr. Raqeeb Haque et al.

For more information on IMAST 2013 please visit:

For NuVasive press materials please visit:

The International Meeting on Advanced Spinal Techniques (IMAST), sponsored by the Scoliosis Research Society, provides an international scientific forum for spine professionals to stay up-to-date on emerging new technologies and techniques. For three days, spine surgeons and other allied health professionals from around the world discuss, debate and demonstrate recent advances in spine surgery.

About NuVasive

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.

NuVasive offers a comprehensive spine portfolio of more than 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company places a large focus on clinical research and support of the Society of Lateral Access Surgery, or SOLAS®, to expand the body of clinical evidence in support of NuVasive's minimally disruptive solutions and to drive adoption of its techniques. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to those risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Investor Contact:
Tina Jacobsen
NuVasive, Inc.
Email Contact

Media Contact:
Nicole Collins
NuVasive, Inc.
Email Contact

Source: NuVasive, Inc.